NYSTATIN — Kesin Pharma Corporation drug label update
The FDA has updated the drug label for Nystatin Oral Suspension, marketed by Kesin Pharma Corporation, confirming its indication for the treatment of oral candidiasis.
This update affects Kesin Pharma Corporation and its regulatory, manufacturing, and quality assurance personnel responsible for nystatin product labeling.
This label update serves as a formal confirmation of the product's clinical application. While the source details are limited, such updates typically reflect a finalized review of the Indications and Usage section, ensuring that promotional claims and clinical applications remain within the scope of authorized use. It suggests that any marketing materials or clinical documentation must align strictly with this therapeutic scope.
Regulatory and quality teams should ensure that all internal product documentation and labeling files reflect the current indication for oral candidiasis treatment. Organizations marketing similar nystatin formulations may wish to review their own labeling for consistency with current standards.
NYSTATIN (Kesin Pharma Corporation). INDICATIONS AND USAGE Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.
Open in openFDA / FDA.gov